ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone510-279-4262
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.93 million
Profitability
Miscellaneous
Employees162
Next Earnings Date5/13/2020 (Estimated)
OptionableNot Optionable
Shockwave Medical (NASDAQ:SWAV) Frequently Asked Questions
What is Shockwave Medical's stock symbol?
Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."
How were Shockwave Medical's earnings last quarter?
Shockwave Medical Inc (NASDAQ:SWAV) announced its quarterly earnings results on Thursday, February, 13th. The company reported ($0.49) EPS for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.02. The firm earned $14.31 million during the quarter, compared to the consensus estimate of $13.34 million. Shockwave Medical had a negative net margin of 119.06% and a negative return on equity of 42.97%. View Shockwave Medical's Earnings History.
When is Shockwave Medical's next earnings date?
What guidance has Shockwave Medical issued on next quarter's earnings?
Shockwave Medical issued an update on its FY 2020
After-Hours earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $74-77 million, compared to the consensus revenue estimate of $75.34 million.
What price target have analysts set for SWAV?
7 equities research analysts have issued 1-year price targets for Shockwave Medical's stock. Their forecasts range from $46.00 to $54.00. On average, they expect Shockwave Medical's share price to reach $49.17 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for Shockwave Medical.
What is the consensus analysts' recommendation for Shockwave Medical?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shockwave Medical.
Has Shockwave Medical been receiving favorable news coverage?
Media headlines about SWAV stock have been trending very negative on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Shockwave Medical earned a daily sentiment score of -3.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Shockwave Medical.
Are investors shorting Shockwave Medical?
Shockwave Medical saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 3,860,000 shares, a decline of 7.2% from the January 15th total of 4,160,000 shares. Based on an average trading volume of 532,700 shares, the days-to-cover ratio is currently 7.2 days. Currently, 18.0% of the company's stock are sold short. View Shockwave Medical's Current Options Chain.
Who are some of Shockwave Medical's key competitors?
Some companies that are related to Shockwave Medical include ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), AtriCure (ATRC), Cardiovascular Systems (CSII), Silk Road Medical (SILK), Atrion (ATRI), Tactile Systems Technology (TCMD), Luminex (LMNX) and Axonics Modulation Technologies (AXNX).
What other stocks do shareholders of Shockwave Medical own?
Who are Shockwave Medical's key executives?
Shockwave Medical's management team includes the folowing people:
- Mr. Douglas E. Godshall, CEO, Pres & Director (Age 54)
- Mr. Daniel Puckett, CFO & Sec. (Age 55)
- Mr. Isaac Zacharias, Chief Commercial Officer (Age 44)
- Mr. Daniel Hawkins, Founder and Sr. Advisor (Age 52)
- Mr. John M. Adams, Co-Founder and Technical Advisor (Age 72)
When did Shockwave Medical IPO?
(SWAV) raised $75 million in an IPO on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
Who are Shockwave Medical's major shareholders?
Shockwave Medical's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (16.49%), Alpine Global Management LLC (2.56%), Capital World Investors (2.07%), Jennison Associates LLC (2.05%), State Street Corp (1.53%) and Lord Abbett & CO. LLC (1.42%). Company insiders that own Shockwave Medical stock include Antoine Papiernik, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias, James E Flynn and Sofinnova Capital Vii Fcpr. View Institutional Ownership Trends for Shockwave Medical.
Which major investors are selling Shockwave Medical stock?
SWAV stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Alyeska Investment Group L.P., Goldman Sachs Group Inc., Cubist Systematic Strategies LLC and NumerixS Investment Technologies Inc. Company insiders that have sold Shockwave Medical company stock in the last year include Antoine Papiernik, Dan Puckett, Douglas Evan Godshall, Frederic H Moll, Isaac Zacharias and Sofinnova Capital Vii Fcpr. View Insider Buying and Selling for Shockwave Medical.
Which major investors are buying Shockwave Medical stock?
SWAV stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC, FMR LLC, Capital World Investors, State Street Corp, Jennison Associates LLC, Lord Abbett & CO. LLC, Point72 Asset Management L.P. and Geode Capital Management LLC. View Insider Buying and Selling for Shockwave Medical.
How do I buy shares of Shockwave Medical?
Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Shockwave Medical's stock price today?
One share of SWAV stock can currently be purchased for approximately $44.82.
How big of a company is Shockwave Medical?
Shockwave Medical has a market capitalization of $1.27 billion and generates $42.93 million in revenue each year. The company earns $-51,110,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Shockwave Medical employs 162 workers across the globe.View Additional Information About Shockwave Medical.
What is Shockwave Medical's official website?
How can I contact Shockwave Medical?
Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at 510-279-4262 or via email at [email protected]
MarketBeat Community Rating for Shockwave Medical (NASDAQ SWAV)
MarketBeat's community ratings are surveys of what our community members think about Shockwave Medical and other stocks. Vote "Outperform" if you believe SWAV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SWAV will underperform the S&P 500 over the long term. You may vote once every thirty days.
